Submit an IND for the CF mRNA program in collaboration with Moderna
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 2 Nov 2021
- Due
- 31 Dec 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Vertex expects to submit an IND for this program in 2022.”
What we found
Evidence strength A What the grades mean
The FDA cleared the VX-522 IND for the Moderna CF mRNA program in December 2022, implying the IND was submitted within 2022. The exact submission date is not stated.
-
A Vertex Pharmaceuticals 10-K filed 2023-02-10
“In December 2022, the FDA cleared our IND for VX-522.” ✓ confirmed on the page
-
A Vertex Pharmaceuticals 10-K filed 2023-02-10
“in December 2022, the U.S. Food and Drug Administration (“FDA”), cleared our Investigational New Drug Application (“IND”) for VX-522, a messenger ribonucleic acid” ✓ confirmed on the page
Market reaction: the shares moved +1.6% against the S&P 500 over the three sessions around the disclosure (9 Feb 2023 to 14 Feb 2023). What this measures
Checked 10 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 2 versions
-
Version 1 · original · stated 2 Nov 2021
Deadline 31 Dec 2022 (“in 2022”) · wording expected
-
Version 2 · stated 5 May 2022
Deadline 31 Dec 2022 (“in 2H 2022”) · wording firm
“In collaboration with Moderna, Vertex is developing CF mRNA therapeutics... Vertex is on track to submit an IND for this program in 2H 2022.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory filing
- Indicative materiality
- Medium rules
- Action
- Submit
- Deliverable
- IND submission for CF mRNA program
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Partner
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Vertex Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-VRTX-006503 · Corrections policy